Hot sale high quality Thiotepa CAS 52-24-4 in stock
Triethylenethiophosphoramide ;Thio-TEPA ;
White crystal powder
Thiotepa CAS:52-24-4 is a polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.
Thiotepa CAS:52-24-4 is an intravenously or locally applied or injected alkylating agent which is currently used in the therapy of breast, ovarian and bladder cancer and for Hodgkin disease. Thiotepa therapy has been associated with low rates of serum enzyme elevations during therapy and very rare instances of acute, clinically apparent injury.
Thiotepa CAS:52-24-4 is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N, N', N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.